These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1659 related articles for article (PubMed ID: 27455225)

  • 21. The role of epithelial-mesenchymal transition-regulating transcription factors in anti-cancer drug resistance.
    Seo J; Ha J; Kang E; Cho S
    Arch Pharm Res; 2021 Mar; 44(3):281-292. PubMed ID: 33768509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigenetic Regulation of Inflammatory Cytokine-Induced Epithelial-To-Mesenchymal Cell Transition and Cancer Stem Cell Generation.
    Markopoulos GS; Roupakia E; Marcu KB; Kolettas E
    Cells; 2019 Sep; 8(10):. PubMed ID: 31557902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition.
    Brown WS; Akhand SS; Wendt MK
    Oncotarget; 2016 Dec; 7(50):83424-83436. PubMed ID: 27825137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
    Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
    Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epithelial-to-mesenchymal transition and cancer stem(-like) cells in head and neck squamous cell carcinoma.
    Chen C; Zimmermann M; Tinhofer I; Kaufmann AM; Albers AE
    Cancer Lett; 2013 Sep; 338(1):47-56. PubMed ID: 22771535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of JAK/STAT3 Signaling in the Regulation of Metastasis, the Transition of Cancer Stem Cells, and Chemoresistance of Cancer by Epithelial-Mesenchymal Transition.
    Jin W
    Cells; 2020 Jan; 9(1):. PubMed ID: 31952344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting ribosome biogenesis as a novel therapeutic approach to overcome EMT-related chemoresistance in breast cancer.
    Ban Y; Zou Y; Liu Y; Lee S; Bednarczyk RB; Sheng J; Cao Y; Wong STC; Gao D
    Elife; 2024 Sep; 12():. PubMed ID: 39259576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deadly crosstalk: Notch signaling at the intersection of EMT and cancer stem cells.
    Espinoza I; Miele L
    Cancer Lett; 2013 Nov; 341(1):41-5. PubMed ID: 23973264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The therapeutic potential of targeting the epithelial-mesenchymal transition in cancer.
    Ginnebaugh KR; Ahmad A; Sarkar FH
    Expert Opin Ther Targets; 2014 Jul; 18(7):731-45. PubMed ID: 24758643
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting lipid metabolism to overcome EMT-associated drug resistance via integrin β3/FAK pathway and tumor-associated macrophage repolarization using legumain-activatable delivery.
    Jin H; He Y; Zhao P; Hu Y; Tao J; Chen J; Huang Y
    Theranostics; 2019; 9(1):265-278. PubMed ID: 30662566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms promoting physiological cells progression into tumorigenesis.
    Korbut E; Ptak-Belowska A; Brzozowski T
    J Physiol Pharmacol; 2012 Dec; 63(6):565-70. PubMed ID: 23388471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor-associated macrophages and epithelial-mesenchymal transition in cancer: Nanotechnology comes into view.
    Vakili-Ghartavol R; Mombeiny R; Salmaninejad A; Sorkhabadi SMR; Faridi-Majidi R; Jaafari MR; Mirzaei H
    J Cell Physiol; 2018 Dec; 233(12):9223-9236. PubMed ID: 30078227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Roles of Dietary Phytoestrogens on the Regulation of Epithelial-Mesenchymal Transition in Diverse Cancer Metastasis.
    Lee GA; Hwang KA; Choi KC
    Toxins (Basel); 2016 May; 8(6):. PubMed ID: 27231938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting the Epithelial-to-Mesenchymal Transition in Cancer Stem Cells for a Better Clinical Outcome of Glioma.
    Lu YB; Sun TJ; Chen YT; Cai ZY; Zhao JY; Miao F; Yang YN; Wang SX
    Technol Cancer Res Treat; 2020; 19():1533033820948053. PubMed ID: 33089751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epithelial-mesenchymal transition and drug resistance: role, molecular mechanisms, and therapeutic strategies.
    Sui H; Zhu L; Deng W; Li Q
    Oncol Res Treat; 2014; 37(10):584-9. PubMed ID: 25342509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Semaphorins as Regulators of Phenotypic Plasticity and Functional Reprogramming of Cancer Cells.
    Gurrapu S; Tamagnone L
    Trends Mol Med; 2019 Apr; 25(4):303-314. PubMed ID: 30824197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The epithelial-mesenchymal transition and cancer stem cells: functional and mechanistic links.
    Liu X; Fan D
    Curr Pharm Des; 2015; 21(10):1279-91. PubMed ID: 25506898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stem cell programs in cancer initiation, progression, and therapy resistance.
    Huang T; Song X; Xu D; Tiek D; Goenka A; Wu B; Sastry N; Hu B; Cheng SY
    Theranostics; 2020; 10(19):8721-8743. PubMed ID: 32754274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer.
    Sun L; Burnett J; Gasparyan M; Xu F; Jiang H; Lin CC; Myers I; Korkaya H; Liu Y; Connarn J; He H; Zhang N; Wicha MS; Sun D
    Oncotarget; 2016 Aug; 7(32):51408-51422. PubMed ID: 27285982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EHMT1/EHMT2 in EMT, cancer stemness and drug resistance: emerging evidence and mechanisms.
    Nachiyappan A; Gupta N; Taneja R
    FEBS J; 2022 Mar; 289(5):1329-1351. PubMed ID: 34954891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 83.